CUBIST PHARMACEUTICALS INC.

Chiron Corporation (Nasdaq:CHIR) and Cubist Pharmaceuticals Inc. (Nasdaq:CBST) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of Chiron's Marketing Authorization Application (MAA) for CUBICIN(R) (daptomycin). CUBICIN is an IV antibiotic being evaluated by the EMEA for the treatment of complicated skin and soft-tissue infections (cSSTI) caused by Gram-positive bacteria.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1109545XSL_NEWSML_TO_NEWSML_WEB.xml)